- the world’s most documented probiotic Bifidobacterium
Bifidobacterium, BB-12® has been scientifically studied and associated with digestive and immune system support.
Chr. Hansen’s Bifidobacterium, BB-12®
Bifidobacteria were discovered and isolated from the stool sample of a breastfed baby in 1899.1 The Chr. Hansen Bifidobacterium, BB-12® originates from our collection of dairy cultures and is used in baby formula, dietary supplements, and fermented milk products (such as yogurt) worldwide.
The BB-12® strain has been described in more than 300 scientific publications, making the BB-12® strain the world’s most documented probiotic Bifidobacterium. More than 200 of these publications are from human scientific studies that investigated the impact of BB-12® across various areas of health, ranging from preterm and newborn babies to the elderly.
The World Health Organisation (WHO) recommends breastfeeding exclusively for the first six months, followed by continued breastfeeding together with complementary foods.2
Bifidobacterium, BB-12® has been associated with numerous health benefits
In babies and children:
Associated with softer and more frequent bowel movements,3 and shorter and fewer episodes of loose stools.4,5
Excessive crying and fussing*
Associated with significantly less excessive crying and fussing in babies.6
Associated with fewer episodes of respiratory discomfort.7, 8, 9
Associated with greater immune system support.10
Associated with fewer instances of red, dry, and scaly skin in babies.11
Associated with lower salivary levels of specific bacteria that contribute to poor oral health.12
Associated with more regular bowel movements in adults13, 14 and the elderly.15
Associated with benefits for immune system function.16
Associated with supporting healthy levels of cholesterol.17
BB-12® is safe for human consumption; it has been granted QPS18 (Qualified Presumption of Safety) status in Europe and has been the subject of a GRAS (Generally Recognized as Safe) notice to the US Food And Drug Administration.19 It has been tested in human scientific studies at levels up to at least 100 billion CFU/day (colony forming units), with no safety issues.
BB-12® is a registered trademark of Chr. Hansen A/S
The article is provided for informational purposes regarding probiotics and is not meant to suggest that any substance referenced in the article is intended to diagnose, cure, mitigate, treat, or prevent any disease.
At Chr. Hansen, our strains are backed by science. All of our probiotic strains are supported by clinical documentation. Learn more about the beneficial effects our strains have on different health areas.
- Jungersen, et al. Microorganisms. 2014;2:92-110. (PubMed)
- World Health Organisation. Accessed 12th November 2021. (Source)
- Vlieger AM, et al. Br J Nutr. 2009;102(6):869-75. (PubMed)
- Weizman Z, et al. Pediatrics. 2005;115(1):5-9. (PubMed)
- Saavedra JM, et al. Lancet. 1994;344(8929):1046-9. (PubMed)
- Nocerino R, et al. Aliment Pharmacol Ther. 2019. (PubMed)
- Taipale TJ, et al. Br J Nutr. 2011;105(3):409-16. (PubMed)
- Taipale TJ, et al. Pediatr Res. 2016;79(1-1):65-9. (PubMed)
- Rautava S, et al. Br J Nutr. 2009;101(11):1722-6. (PubMed)
- Holscher HD, et al. J Parenter Enteral Nutr. 2012;36(1 Suppl):106s-17s. (PubMed)
- Isolauri E, et al. Clin Exp Allergy. 2000;30(11):1604-10. (PubMed)
- Caglar E, et al. Acta Odontol Scand. 2008;66(3):154-8. (PubMed)
- Eskesen D, et al.Br J Nutr. 2015;114(10):1638-46. (PubMed)
- Uchida K, et al. Journal of Nutritional Food. 2005;8:39-51.
- Pitkala KH, et al. J Nutr Health Aging. 2007;11(4):305-11. (PubMed)
- Rizzardini G, et al. Br J Nutr. 2012;107(6):876-84. (PubMed)
- Ejtahed HS, et al. J Dairy Sci. 2011;94(7):3288-94. (PubMed)
- EFSA Panel on Biological Hazards (BIOHAZ). EFSA Journal. 2015;13:4331.
- Food and Drug Administration. GRAS Notice Inventory > Agency Response Letter GRAS Notice No GRN 000049. 2002.